Showing results (131-140 of 212) with videos related to
Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.The Lancet. Oncology|July 24, 2017
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J Overman, Ray McDermott, Joseph L Leach, et al.Journal of the National Cancer Institute|May 3, 2018
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal CancerJonathan M Loree, Ann M Bailey, Amber M Johnson, et al.Annals of Surgical Oncology|November 12, 2025
Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous NeoplasmsAshlee N Seldomridge, Michael G White, Christopher Scally, et al.Clinical Colorectal Cancer|February 4, 2020
Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal CancerShailesh M Advani, Quilling Shi, Michael J Overman, et al.European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.Annals of Surgical Oncology|October 23, 2023
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable BenefitNeal Bhutiani, Travis E Grotz, Seth J Concors, et al.Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.Pageof 22